Progressive accumbens degeneration after neonatal striatal 6- hydroxydopamine in rats

Neuroscience Letters

Volumn 247, Issue 2-3, 1998, Pages 99-102

  Teicher, Martin H ^a,b   Andersen, Susan L ^a,b   Campbell, Alexander ^a,b   Gelbard, Harris A ^a   Baldessarini, Ross J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Labs Psychiat Res Mailman R   (United States)

Author keywords

6 hydroxydopamine; Caudate putamen; Models; Nucleus accumbens septi; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; NERVE FIBER DEGENERATION; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANIMALS, NEWBORN; CAUDATE NUCLEUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; DOPAMINE; HOMOVANILLIC ACID; NERVE DEGENERATION; NEUROTOXINS; NUCLEUS ACCUMBENS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032524888     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00281-X     Document Type: Article

References (20)

1. 3H]Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 99:1984;167-175.
2. Chiueh C.C., Huang S.J., Murphy D.L. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse. 11:1992;346-348.
3. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 51:1988;745-752.
4. Goldstein M., Lieberman A., Pearson J. Relatively high levels of dopamine in nucleus accumbens of levodopa treated patients with Parkinson's disease. J. Neural Transm. 54:1982;129-134.
5. Hastings T.G., Lewis D.A., Zigmond M.J. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv. Exp. Med. Biol. 387:1996;97-106.
6. Hornykiewicz O. Parkinson's disease: from brain homogenate to treatment. Fed. Proc. 32:1973;183-190.
7. Kelley A.E., Domesick V.B. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde- and retrograde-horseradish peroxidase study. Neuroscience. 7:1982;2321-2335.
8. Koob G.F., Swerdlow N.R. The functional output of the mesolimbic dopamine system. Ann. NY Acad. Sci. 537:1988;216-227.
9. Lerner, A.J., Strauss, M.E. and Whitehouse, P.J., Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. In S.C. Yodofsky and R.E. Hales (Eds.), The American Psychiatric Press Textbook of Neuropsychiatry, American Psychiatric Press, Washington DC, 1997, pp. 799-822.
10. Nieoullon A., Cheramy A., Glowinski J. Interdependence of the nigrostriatal dopaminergic systems on the two sides of the brain in the cat. Science. 198:1977;416-418.
11. Oyanagi K., Makifuchi T., Ohtoh T., Chen K.M., Gajdusek D.C., Chase T.N., Ikuta F. The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy. Acta Neuropathol. 88:1994;122-128.
12. Rinne J.O., Halonen T., Riekkinen P.J., Rinne U.K. Free amino acids in the brain of patients with Parkinson's disease. Neurosci. Lett. 94:1988;182-186.
13. Rinne J.O., Roytta M., Paljarvi L., Rummukainen J., Rinne U.K. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology. 41:1991;859-861.
14. Rose S.J., Nomoto M., Jenner P., Marsden C.D. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochem. Pharmacol. 38:1989;3677-3681.
15. Sherwood, N.M. and Timeras, P.S. A Stereotaxic Atlas of the Developing Rat Brain, University of California Press, Berkeley, CA, 1970.
16. Smith J.A., Hartley R. Abnormal O-methylated dopamine metabolites: the endogenous toxins of schizophrenia or parkinsonism? J. Pharm. Pharmacol. 25:1973;415-416.
17. Spencer J.P., Jenner A., Aruoma O.I., Evans P.J., Kaur H., Dexter D.T., Jenner P., Lees A.J., Marsden D.C., Halliwell B. Intense oxidative DNA damage promoted by L-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 353:1994;246-250.
18. Teicher M.H., Barber N.I., Gelbard H.A., Galittano A.L., Campbell A., Marsh E., Baldessarini R.J. Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology. 9:1993;147-156.
19. Zigmond M.K., Stricker E.M. Parkinson's disease: studies with an animal model. Life Sci. 35:1984;5-18.
20. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1984;290-296.